Ahmed Jouan
Neurology · Quincy, ILNPI 1043766314
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $6,495 of the $9,488 with a category attached, or 68.5%. 40 manufacturers reported payments, led by Livanova USA, Inc. at 34.1% of the total. Reporting peaked in 2023 at $3,546 and has fallen 88.6% since, to $406 in 2025.
Across 271 payments — averaging $35.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Livanova USA, Inc.$3K
- AbbVie$664
- Medtronic$509
- Biogen$481
- Neurocrine Biosciences, Inc.$415
- Ceribell, Inc.$313
- plus $4K from 34 others
Across 30 payments — averaging $1794.33 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Janssen Research & Development, LLC$54K
What the payments were for
- Consulting fees$3003%
- Travel & lodging$2,65928%
- Food & beverage$6,49568%
- Education$340%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Livanova USA, Inc. | 19 | $3,231 |
| AbbVie(2 entities) | 40 | $664 |
| Medtronic | 5 | $509 |
| Biogen | 8 | $481 |
| Neurocrine Biosciences, Inc. | 21 | $415 |
| Ceribell, Inc. | 2 | $313 |
| Bristol Myers Squibb | 29 | $307 |
| SK Life Science, Inc. | 7 | $305 |
| Lundbeck LLC | 12 | $251 |
| Lilly USA, LLC | 18 | $249 |
| Sanofi | 3 | $244 |
| Novartis | 7 | $237 |
| Neurelis, Inc. | 4 | $220 |
| Kyowa Kirin, Inc. | 4 | $162 |
| Sumitomo Pharma America, Inc. | 9 | $154 |
| Genentech USA, Inc. | 8 | $152 |
| Amneal Pharmaceuticals LLC | 8 | $141 |
| UCB, Inc. | 8 | $135 |
| Pfizer | 6 | $112 |
| Portola Pharmaceuticals, LLC | 1 | $110 |
| Eisai Inc. | 6 | $110 |
| Acadia Pharmaceuticals Inc | 3 | $100 |
| CSL Behring | 1 | $99 |
| Teva Pharmaceuticals USA, Inc. | 5 | $94 |
| Argenx US, Inc. | 4 | $76 |
| Tanabe Pharma America, Inc. | 4 | $70 |
| Acorda Therapeutics, Inc | 4 | $66 |
| Harmony Biosciences LLC | 4 | $62 |
| EMD Serono, Inc. | 3 | $58 |
| Grifols USA, LLC | 3 | $56 |
| Amgen | 3 | $53 |
| AstraZeneca | 2 | $47 |
| Merz Pharmaceuticals, LLC | 2 | $41 |
| Boston Scientific | 1 | $39 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $32 |
| Avion Pharmaceuticals | 1 | $21 |
| Ipsen Biopharmaceuticals, Inc | 1 | $19 |
| Catalyst Pharmaceuticals, Inc. | 1 | $19 |
| Johnson & Johnson | 1 | $18 |
| Sunovion Pharmaceuticals Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VNS Therapy$2,175
- VNS - Sentiva$959
- PERCEPT PC BRAINSENSE$429
- Ceribell Rapid Response EEG$300
- INGREZZA$128
- XCOPRI$122
- GILENYA$121
- AUBAGIO$120
- NOURIANZ$112
- ANDEXXA$110
How this compares
$9,488 in reported general payments places this provider in the 80th percentile of 790 neurology providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Nurtec OdtRimegepant Sulfate | 56 | $72,419 |
| Aimovig AutoinjectorErenumab-Aooe | 75 | $59,867 |
| BriviactBrivaracetam | 26 | $50,447 |
| Pyridostigmine Bromide | 20 | $20,658 |
| Lacosamide | 77 | $7,859 |
| Gabapentin | 205 | $5,462 |
| Levetiracetam | 194 | $5,270 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 295 | $3,664 |
| Primidone | 172 | $3,588 |
| Memantine Hcl | 115 | $3,303 |
| Oxcarbazepine | 34 | $3,207 |
| Pregabalin | 17 | $2,677 |
| Rasagiline Mesylate | 17 | $2,619 |
| Duloxetine Hcl | 57 | $2,458 |
| Zonisamide | 97 | $1,917 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerNurtec Odt | $112 | $72,41956 claims |
| UCB, Inc.Briviact | $135 | $50,44726 claims |
| Amneal Pharmaceuticals LLCPyridostigmine Bromide | $141 | $20,65820 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 790 neurology providers in Illinois.
Other neurology in Quincy
- Augusto MiravalleChicago$1.4M
- Lori GuytonHerrin$1.1M
- Daniel WynnNorthbrook$812K
- Arthur ItkinPalos Heights$808K
- Andrew GordonLake Barrington$765K
- Martha McGrawWinfield$625K
- Reuben ValenzuelaPeoria$590K
- Adil JavedChicago$584K
- Tyler KaplanMaywood$549K
- Danny BegaChicago$442K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.